Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study.

Shintaro NakanoSatoshi YukiYasuyuki KawamotoHiroshi NakatsumiTakayuki AndoShinya KajiuraAyumu YoshikawaKazuaki HaradaKazuteru HatanakaAya TanimotoAtsushi IshiguroTakuya HondaMasayoshi DazaiTakahide SasakiNaoya SakamotoYoshito Komatsu

Published in: International journal of clinical oncology (2020)

There was no significant difference in the efficacy of irinotecan monotherapy between UGT1A1 WT and UGT1A1 SH, but UGT1A1 SH was associated with a high frequency of severe hematological toxicity.

Keyphrases

high frequency
transcranial magnetic stimulation
early onset
combination therapy
open label
oxidative stress
double blind